Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: GSK | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: GSK

Revenues drop 10% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

GSK
 
1Q Revenues: £5.6 billion (-10%)
 
1Q Earnings: £1.5 billion (-18%)
 
Comments: Pharmaceutical sales were £3.8 billion, down 4% and Vaccines sales were £658 million, up 3% with growth in Europe (+3%), Emerging Markets (+2%), Japan (+13%), offset by a 10% decline in the U.S., impacted by continued Advair declines (-20%) and quarterly volatility in wholesaler/retailer stocking patterns. HIV sales were up 4%, driven by uptake of recently launched integrase inhibitor, Tivicay. Oncology product sales were up 31% to £108 million, driven by Votrient and Promacta, and the recent launches of Tafinlar and Mekinist. Consumer Healthcare revenue was flat at £1.1 million. In the quarter, the company announced a $20 billion three-part deal with Novartis involving its Consumer Healthcare, Vaccines and Oncology businesses.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters